Cardiovascular risk and HIV infection;Riesgo vascular e infección por el virus de la inmunodeficiencia humana tipo 1

Medicina Clinica

Volumn 122, Issue 8, 2004, Pages 301-303

  Dronda, Fernando ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROTEINASE INHIBITOR; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL FEATURE; DIABETES MELLITUS; DISEASE ACTIVITY; DISEASE ASSOCIATION; EDITORIAL; EPIDEMIOLOGICAL DATA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; PUBLICATION; SPAIN;

EID: 1942454916     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13058676     Document Type: Editorial

References (22)

1. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome. Prevalence and associated risk factor findings in the US population from the third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 2003;163:427-36.
2. Hernández-Mijares A, Riera-Fortuny C, Solá-Izquierdo E, Oliver-Oliver MJ, Martínez-Triguero ML, Morillas-Ariño C, et al. Prevalencia del síndrome metabólico en pacientes con cardiopatía isquémica. Med Clin (Barc) 2003;121:204-8.
3. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovascul Risk 1996;3:213-9.
4. Rosenson RS, Shott S, Lu L, Tangney CC. Hypertriglyceridemia and other factors associated with plasma viscosity. Am J Med 2001;110:488-92.
5. Henry K, Melroe H, Huebsch J, Hermundson J, Levine C, Swensen L, et al. Severe premature coronary artery disease with protease inhibitors [letter]. Lancet 1998;351:1328.
6. Behrens G, Schmidt H, Meyer, Stoll M, Schmidt RE. Vascular complications associated with the use of HIV protease inhibitors [letter]. Lancet 1998;351:1958.
7. Gallet B, Pulik M, Genet P, Chedin P, Hitgen M. Vascular complications associated with use of HIV protease inhibitors [letter]. Lancet 1998;351:1958-9.
8. Vittecoq D, Escaut L, Monsuez JJ. Vascular complications associated with the use of HIV protease inhibitors [letter]. Lancet 1998;351:1959.
9. Friis-Møller N, Weber R, Reiss P, Thiébaut R, Kirk O, D'Arminio Monforte A, et al. Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study. AIDS 2003;17:1179-93.
10. Dubé MP, Sprecher D, Henry WK, Aberg JA, Torriani FJ, Hodis HN, et al. Preliminary guidelines for the evaluation and management of dyslipemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group. Clin Infect Dis 2000;31:1216-24.
11. Martínez E, Fernández-Miranda C, Conget I, Moreno S, Santamaria JM, Boix V, et al. Actitud ante las alteraciones metabólicas y de distribución de la grasa corporal en pacientes infectados por el virus de la inmunodeficiencia humana que reciben tratamiento antirretroviral. En: Grupo de Estudio de Sida (GESIDA) de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC). Documentos de Consenso de GESIDA. Terapia antirretroviral y enfermedades asociadas al VIH (2000-2002). Madrid: Doyma, 2002; p. 157-71.
12. Mauss S, Stechel J, Willers R, Schmutz G, Berger F, Richter WO. Differentiating hyperlipidaemia associated with antiretroviral therapy. AIDS 2003;17:189-94.
13. Jericó C, Knobel H, Carmona A, Sorli ML, Ló pez-Colomés JL, Pedro-Botet J. Enfermedad cardiovascular sintomática en pacientes infectados por el virus de la inmunodeficiencia humana que reciben tratamiento antirretroviral. Med Clin (Barc) 2003;122:298-300.
14. Holmberg SD, Moorman AC, Williamson JM, Tong TC, Ward DJ, Wood KC, et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002;360:1747-8.
15. th Conference on Retroviruses and Opportunistic Infections; 2003, February; Boston 2003 [abstract 130].
16. David MH, Hornung R, Fichtembaum CJ. Ischemic cardiovascular disease in persons with human immunodeficiency virus infection. Clin Infect Dis 2002;34:98-102.
17. Dronda F, Moreno S, Pérez-Elías MJ, Casado JL, Antela A, Moreno A. Vascular disease in HIV-infected patients: a comparative study of two different therapeutic periods (1994-1997 versus 1998-2000). AIDS 2002;16:1971-4.
18. Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003;348:702-10.
19. Torre D, Pugliese A, Orofino G. Effect of highly active antiretroviral therapy on ischemic cardiovascular disease in patients with HIV-1 infection. Clin Infect Dis 2002;35:631-2.
20. th Conference on Retroviruses and Opportunistic Infections; 2003, February, Boston [abstract 747].
21. Hadigan C, Meigs JB, Wilson PWF, D'Agostino RB, Davis B, Basgoz N, et al. Prediction of coronary heart disease risk in HIV-infected patients with fat redistribution. Clin Infect Dis 2003;36:909-16.
22. Currier JS, Taylor A, Boyd F, Dezii CM, Kawabata H, Burtcel B, et al. Coronary Heart Disease in HIV-Infected Individuals. J Acquir Immune Defic Syndr 2003;33:506-12.